

---

**CMV Detection and Treatment: At the Crossroads of Immunity and Pathogen**  
**Virtual Symposium – Saturday, May 30, 2020 | 12:25 pm – 1:25 pm**

---

**Target Audience**

This activity is intended for physicians and other healthcare providers engaged in managing CMV in transplant patients.

---

**Learning Objectives**

Upon completion of the educational activity, participants should be able to:

- Select appropriate treatments for patients with CMV infection following transplant based on efficacy data and guideline recommendations.
  - Identify patients with antiviral-resistant or refractory CMV and offer treatments that are appropriate for these patients.
  - Assess side effect profiles of antiviral therapy in order to guide CMV treatment selection.
- 

**Faculty**

Lara Danziger-Isakov, MD, MPH – *CHAIR*  
Professor of Pediatrics  
Director, Immunocompromised Host Infectious Diseases  
Cincinnati Children’s Hospital Medical Center  
University of Cincinnati  
Cincinnati, OH

Camille Nelson Kotton MD, FIDSA, FAST  
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases  
Infectious Diseases Division  
Massachusetts General Hospital  
Harvard Medical School  
Boston, MA

Raymund R Razonable, MD, FIDSA, FAST  
Professor of Medicine  
Program Director, Infectious Diseases Fellowship Program  
Vice Chair, Division of Infectious Diseases  
Mayo Clinic  
Rochester, MN

**Agenda**

***Featuring a Heart Transplant Patient Panelist***

- |                    |  |
|--------------------|--|
| 12:25 PM-12:30 PM  | Welcome and Introductions<br><br><i>Lara A. Danziger-Isakov, MD, MPH</i>   |
| 12:30 PM- 12:50 PM | Challenges and Treatments in CMV: The Patient Perspective<br><br>Featuring an Experienced CMV Patient’s Testimonial<br><br><i>Camille N. Kotton, MD, FIDSA, FAST and Panel</i> |
| 12:50 PM-1:10 PM   | CMV Prevention and Delayed-Onset Disease<br><br>Featuring a double organ transplant patient case with CMV<br><br><i>Raymund R. Razonable, MD, FIDSA, FAST and Panel</i>        |
| 1:10 PM-1:25 PM    | Audience Q&A and Closing Remarks<br><br><i>All Faculty</i>   |



CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

**Physicians**

---

---

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

#### Physician Assistants

NCCPA accepts *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points 0 patient safety in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

#### Criteria for Success

Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form. If you have questions about this activity, please contact AKH Inc. at [tbrignoni@akhcme.com](mailto:tbrignoni@akhcme.com).

---

#### FACULTY DISCLOSURES

**Lara Danziger-Isakov, MD, MPH** has disclosed the following relevant financial relationships: Merck, Takeda/Shire (Consultant); Astellas Ansun Biopharma, Merck, Shire-Takeda, Viracor (Contracted Research)

**Camille Nelson Kotton, MD, FIDSA, FAST** has disclosed the following relevant financial relationships: Hookipa, Merck, Roche Diagnostics, Shire/Takeda (Consultant)

**Raymund R. Razonable, MD, FIDSA, FAST** has disclosed the following relevant financial relationships: Roche (Contracted Research)

**Peter Arnone – Patient** has disclosed no financial relationships.

#### STAFF AND REVIEWERS DISCLOSURES

RMEI Medical Education, LLC planners and managers have no financial relationships to disclose.

Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer: has disclosed no financial relationships.

Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.

#### COMMERCIAL SUPPORT

This educational activity is supported by an independent medical educational grant from Takeda.

#### DISCLOSURE DECLARATION

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

#### DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

#### DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

---